Physician profile
Heidi E Rodillo
NPI 1124194451
$8,575.14
in general payments reported to CMS, 2019-2025
61 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $919 · 2021: $1,013 · 2022: $1,460 · 2023: $1,528 · 2024: $1,193 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,009.58 | 2019-2025 | Evenity, Otezla, Repatha |
| Lundbeck LLC | $701.64 | 2022-2025 | Vyepti, Rexulti |
| Abbvie INC. | $531.73 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $527.09 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $475.42 | 2020-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.71 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $442.51 | 2019-2025 | Breztri, Farxiga |
| Abbott Laboratories | $381.24 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $359.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $249.70 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $241.61 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.74 | 2021-2025 | Hyqvia, Trintellix |
| Daiichi Sankyo INC. | $231.52 | 2020-2025 | Injectafer |
| Lilly USA, LLC | $218.87 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Insulet Corporation | $204.25 | 2019-2023 | Omnipod |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Rodillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.